Jump to content
  • Dossier Advanced therapy medicinal products

    Novel gene and cell therapies are associated with high expectations in the treatment of incurable and hereditary diseases. Among them, CAR-T cell therapies have emerged as a major hope in cancer treatment.
    © BIOPRO Baden-Württemberg GmbH

  • Contact Stay in touch

    Would you like continue receiving e-mail notifications about our activities, up-to-date information, events, opportunities for cooperation and general industry information? Register here to stay informed about current issues.
    © denisismagilov / Adobe Stock

  • Industry report The healthcare industry in Baden-Württemberg

    BIOPRO's new report entitled "Healthcare Industry 2020: Facts and Figures for Baden-Württemberg" illustrates key figures like num the number of companies, number of employees and taxable turnover for the biotechnology, medical technology and pharmaceutical industry.
    © MR.LIGHTMAN / Adobe Stock

Latest news

  • Press release - 02/04/2024

    In the medicine of the future, tiny robots will navigate independently through tissue and medical instruments will indicate their position inside the body during surgery. Both require doctors to be able to localize and control the devices precisely and in real time. Scientists from the German Cancer Research Center (DKFZ) have now described a signaling method based on an oscillating magnet that can significantly improve such medical applications.

  • Epifadin from the nasal microbiome - 28/03/2024

    Antibiotics are becoming an increasingly blunt weapon against infectious diseases. The number of (multi-)resistant germs has been rising rapidly for years and even reserve antibiotics no longer work. Researchers at the University of Tübingen have now isolated a completely new antibiotic substance called epifadin from the microbiome of the human nose. It is effective against many different bacteria - including the dangerous hospital MRSA.

  • Press release - 27/03/2024

    Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for the treatment of multiple myeloma to its lead candidate HDP-101. Heidelberg Pharma is investigating the candidate in a clinical Phase I/IIa study for the treatment of relapsed/refractory multiple myeloma (RRMM).

  • Press release - 22/03/2024

    Researchers from the Max Planck Institute for Biology Tübingen broke new ground by demonstrating that an HMG-box gene in brown algae is crucial for determining male sex. This breakthrough significantly expands our understanding of sex-determination mechanisms in eukaryotic organisms. Until now, master sex-determination genes had been identified in only a select number of animals and plants.

Website address: https://www.gesundheitsindustrie-bw.de/en